TY - JOUR
T1 - New issues in systemic therapy for ovarian cancer
AU - Armstrong, Deborah K.
PY - 2013/5/1
Y1 - 2013/5/1
N2 - Most patients with ovarian cancer require systemic therapy upfront and again on recurrence. Treatment advances over the past decade have been few, but bevacizumab prolongs disease remission, if not survival. Other targeted agents have not been effective, but emerging data for experimental agents suggest this outlook may change. In her presentation at the NCCN 18th Annual Conference, Dr. Deborah K. Armstrong reviewed findings supporting intraperitoneal chemotherapy, the use of bevacizumab, the use of neoadjuvant chemotherapy, and the potential of poly (ADP-ribose) polymerase (PARP) inhibitors and other newer agents.
AB - Most patients with ovarian cancer require systemic therapy upfront and again on recurrence. Treatment advances over the past decade have been few, but bevacizumab prolongs disease remission, if not survival. Other targeted agents have not been effective, but emerging data for experimental agents suggest this outlook may change. In her presentation at the NCCN 18th Annual Conference, Dr. Deborah K. Armstrong reviewed findings supporting intraperitoneal chemotherapy, the use of bevacizumab, the use of neoadjuvant chemotherapy, and the potential of poly (ADP-ribose) polymerase (PARP) inhibitors and other newer agents.
UR - http://www.scopus.com/inward/record.url?scp=84887238283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887238283&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2013.0203
DO - 10.6004/jnccn.2013.0203
M3 - Article
C2 - 23704245
AN - SCOPUS:84887238283
SN - 1540-1405
VL - 11
SP - 690
EP - 693
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5 SUPPL.
ER -